Track market-moving stories before they get noisy

NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Azenta, Inc. (“Azenta” or the “Company”) (NASDAQ: AZTA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation concerns whether Azenta and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]

On August 24, 2026, Azenta issued a press release announcing the resignation of John Marotta from his roles as Chief Executive Officer and as a director of the Company.

On this news, Azenta’s stock price fell $4.52 per share, or 12.09%, to close at $32.88 per share on August 24, 2026.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Azenta, Inc. ("Azenta" or the "Company") (NASDAQ: AZTA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation concerns whether Azenta and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On August 24, 2026, Azenta issued a press release announcing the resignation of John Marotta from his roles as Chief Executive Officer and as a director of the Company. 

On this news, Azenta's stock price fell $4.52 per share, or 12.09%, to close at $32.88 per share on August 24, 2026.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes. 

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

SOURCE Pomerantz LLP

NEW YORK, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Azenta, Inc. (“Azenta” or the “Company”) (NASDAQ: AZTA).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation concerns whether Azenta and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On August 24, 2026, Azenta issued a press release announcing the resignation of John Marotta from his roles as Chief Executive Officer and as a director of the Company. 

On this news, Azenta’s stock price fell $4.52 per share, or 12.09%, to close at $32.88 per share on August 24, 2026.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Azenta, Inc. ("Azenta" or the "Company") (NASDAQ: AZTA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation concerns whether Azenta and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On August 24, 2026, Azenta issued a press release announcing the resignation of John Marotta from his roles as Chief Executive Officer and as a director of the Company. 

On this news, Azenta's stock price fell $4.52 per share, or 12.09%, to close at $32.88 per share on August 24, 2026.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes. 

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

SOURCE Pomerantz LLP

Current Director Dr. Martin Madaus Appointed Interim CEO

Company Reaffirms Previously Announced Fourth Quarter Fiscal 2026 Total Revenue Guidance

, /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) ("Azenta" or "the Company") today announced that current member of the Board of Directors (the "Board") Dr. Martin Madaus has been appointed interim President and CEO, and that John Marotta has resigned as an executive officer and director of the Company.

Dr. Madaus has served in multiple CEO roles in the diagnostics and life science tools industry and joined the Azenta Board in 2024 – making him the ideal individual to lead the Company during this transition. He is a Senior Operating Executive at the Carlyle Group Inc. (Nasdaq: CG) and has a proven track record of creating shareholder value in both public and private life science companies. Notably, he has served as Chairman, President and CEO of Millipore Corporation, Chairman and CEO of Ortho-Clinical Diagnostics, and President and CEO of Roche Diagnostics North America, a subsidiary of Roche Holding AG.

The Board has retained leading search firm Heidrick & Struggles, and a search process for a permanent CEO is underway. Additionally, the Company is reaffirming its fourth quarter fiscal 2026 total revenue guidance previously issued on August 4, 2026. The Company now expects fourth quarter fiscal 2026 adjusted EBITDA to be impacted by a one-time approximately $3 million consulting expense that will be recorded in the fourth quarter. Excluding this one-time charge, the Company would be reaffirming adjusted EBITDA as well.

Frank E. Casal, Chairman of the Azenta Board, said, "Azenta's focus remains on executing our long-range strategic plan to drive profitable, sustainable value creation. The Board regularly analyzes the performance of our core business units and will continue to evaluate which areas merit targeted reinvestments, while also maintaining a disciplined approach to capital deployment. As discussed on our third quarter earnings call earlier this month, we have seen notable progress in terms of revenue and profitability, and the Board is confident that Martin is the ideal choice to help build on this positive momentum and guide Azenta during this transition period. His track record of successful leadership in our sector speaks for itself, and we believe his deep familiarity with our businesses from his time on the Board will help allow for a seamless transition for our customers, partners, and employees."

Dr. Madaus said, "I am pleased to be taking on this role and look forward to leading Azenta as we continue to focus on disciplined execution and advancing key initiatives in support of our strategic plan. I have long admired Azenta as a leader in the space and believe that, with the support of the Company's incredibly talented team, we can accelerate our efforts to meet our commitments and deliver value for shareholders."

Mr. Casal continued, "On behalf of the Board, I would like to thank John for his contributions to Azenta."

Dr. Martin Madaus Full Biography
Dr. Martin Madaus has more than 30 years of leadership experience in diagnostics and life science tools, both as an executive and a board member. He is a Senior Operating Executive at the Carlyle Group Inc. (Nasdaq: CG), a global investment firm with $485 billion in assets under management. In addition to the Board of Azenta, he also currently serves as Chair of the Board of Repligen Corporation and as a director at Haemonetics Corporation (NYSE: HAE).

He previously served as Chairman and CEO at Ortho-Clinical Diagnostics (now QuidelOrtho Corporation), Chairman, President and CEO of Millipore Corporation, and President and CEO of Roche Diagnostics North America, a subsidiary of Roche Holding AG (SWX: ROG).

He earned a Doctor of Veterinary Medicine Degree from the University of Munich, Germany, and a Ph.D. in Veterinary Medicine from the Veterinary University of Hannover, Germany.

"Safe Harbor Statement" under Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended
Some statements in this release are forward-looking statements made under Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are neither promises nor guarantees but involve risks and uncertainties, both known and unknown, that could cause Azenta's actual financial and business results to differ materially from those expressed or implied by such statements. They are based on the facts and assumptions known to management at the time they are made. Forward looking statements include, but are not limited to, statements regarding the Company's guidance, the Company's long-range plan, the Company's analyses of its core business units and its investments and capital deployment and the Company's expectations with respect to Dr. Madaus' role as Interim President and CEO and his impact on the Company's business, customers, partners, employees and shareholders.

Factors that could cause actual results to differ materially from those expressed or implied by forward looking statements include, but are not limited to: the Company's ability to ensure a smooth CEO transition; the Company's ability to execute on and realize the expected benefits from its transformation and operational improvement initiatives; changes in customer demand, purchasing behavior or funding conditions in the markets the Company serves; macroeconomic, geopolitical or regulatory developments; the impact of foreign currency fluctuations; the Company's ability to effectively manage costs, improve productivity and achieve anticipated margin improvements; supply chain disruptions; competitive dynamics; the ability of customers to meet payment obligations; risks relating to the collectability and timely repayment of the $35 million secured vendor loan extended to the buyer in connection with the B Medical Systems divestiture, including the buyer's ability to obtain permanent financing, the sufficiency of the collateral securing the loan, and the potential for an associated charge or impairment; and other risks and uncertainties described in the Company's filings with the Securities and Exchange Commission, including but not limited to its Annual Report on Form 10 K, Quarterly Reports on Form 10 Q and Current Reports on Form 8 K. Because forward looking statements relate to future events and are based on current expectations, they are inherently subject to significant uncertainties, particularly with respect to projections and assumptions extending over multiple years. As a result, actual outcomes may differ materially from those projected. Azenta expressly disclaims any obligation or undertaking to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

About Azenta Life Sciences
Azenta, Inc. (Nasdaq: AZTA) is a leading provider of life sciences solutions worldwide, enabling life science organizations around the world to bring impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and multiomics services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. Our global team delivers and supports these products and services through our industry-leading brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, and Barkey.

Azenta is headquartered in Burlington, Massachusetts, with operations in North America, Europe, and Asia. For more information, please visit www.azenta.com.

AZENTA INVESTOR CONTACTS:
Yvonne Perron
Vice President, Financial Planning & Analysis and Investor Relations
[email protected]

Maria Isabel Cuartas
Manager Investor Relations
[email protected]

AZENTA MEDIA CONTACT:
Joe Germani / Dan Zacchei
Longacre Square Partners
[email protected]

SOURCE Azenta

Posted by Defense World Staff on Aug 6th, 2026

Arrowstreet Capital Limited Partnership purchased a new position in Azenta, Inc. (NASDAQ:AZTA – Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 71,410 shares of the company’s stock, valued at approximately $1,509,000. Arrowstreet Capital Limited Partnership owned approximately 0.15% of Azenta as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also modified their holdings of the company. Caitong International Asset Management Co. Ltd raised its holdings in shares of Azenta by 2,067.6% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 802 shares of the company’s stock worth $27,000 after buying an additional 765 shares during the last quarter. Assetmark Inc. grew its holdings in shares of Azenta by 54.1% during the fourth quarter. Assetmark Inc. now owns 832 shares of the company’s stock valued at $28,000 after buying an additional 292 shares during the last quarter. State of Wyoming acquired a new position in shares of Azenta in the 1st quarter valued at $38,000. Osaic Holdings Inc. raised its stake in Azenta by 44.9% in the 2nd quarter. Osaic Holdings Inc. now owns 1,242 shares of the company’s stock worth $39,000 after acquiring an additional 385 shares during the last quarter. Finally, Rockefeller Capital Management L.P. lifted its position in Azenta by 98.0% during the 4th quarter. Rockefeller Capital Management L.P. now owns 1,392 shares of the company’s stock worth $46,000 after acquiring an additional 689 shares during the period. Hedge funds and other institutional investors own 99.08% of the company’s stock.

Azenta Stock Performance AZTA opened at $31.76 on Thursday. Azenta, Inc. has a fifty-two week low of $15.93 and a fifty-two week high of $41.73. The company has a fifty day moving average of $25.28 and a two-hundred day moving average of $25.55. The stock has a market capitalization of $1.46 billion, a price-to-earnings ratio of -11.51 and a beta of 1.37.

Azenta (NASDAQ:AZTA – Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The company reported $0.16 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.11 by $0.05. The company had revenue of $161.18 million for the quarter, compared to the consensus estimate of $149.31 million. Azenta had a positive return on equity of 1.15% and a negative net margin of 20.63%.

Analysts Set New Price Targets Several brokerages have recently issued reports on AZTA. Weiss Ratings upgraded Azenta from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, July 15th. Needham & Company LLC upped their target price on Azenta from $33.00 to $37.00 and gave the company a “buy” rating in a research report on Wednesday. Four equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Azenta presently has an average rating of “Hold” and a consensus price target of $41.20.

Get Our Latest Report on Azenta

Azenta News Roundup Here are the key news stories impacting Azenta this week:

Positive Sentiment: Strong quarterly beat: Azenta reported adjusted EPS of $0.16, topping the $0.11 analyst consensus, while revenue reached $161.18 million versus expectations of $149.31 million. The results signal better-than-expected operating performance and demand. Azenta Reports Third Quarter Results for Fiscal 2026 Positive Sentiment: Raised revenue outlook: Azenta projected fiscal 2026 revenue of $613 million to $618 million, above the $597.3 million consensus estimate. The guidance suggests management expects growth to continue and supports the stronger earnings reaction. Positive Sentiment: Needham became more bullish: Needham & Company raised its price target from $33 to $37 and assigned a “Buy” rating, implying roughly 16.5% potential upside based on the reference price. Benzinga analyst rating report Positive Sentiment: Insider buying: Senior Vice President Ephraim Starr purchased 335 AZTA shares for approximately $8,097, modestly increasing his direct ownership. While small relative to the company’s market value, the purchase may reinforce confidence among investors. SEC insider transaction filing Neutral Sentiment: Valuation remains mixed: One analysis described Azenta as undervalued relative to sales but fairly valued based on cash flow, suggesting that the earnings beat and growth outlook are attractive but some of the optimism may already be reflected in the stock. Neutral Sentiment: Brokerage consensus: The average analyst target was reported at $40.40, providing additional potential upside, although target prices are estimates rather than guarantees. Azenta continues to report a negative net margin, which remains a financial risk despite the quarterly beat. Azenta Profile (Free Report)

Azenta, Inc (NASDAQ: AZTA) is a life sciences technology company specializing in sample management, cryogenic storage and genomic services for research and clinical applications. Formerly the Life Sciences division of Brooks Automation, Azenta provides integrated solutions that enable customers to store, track and analyze biological samples with high levels of automation, data integrity and efficiency. Its offerings span automated storage systems, biorepository management software and end‐to‐end sample tracking workflows.

In addition to hardware and informatics platforms for sample storage, Azenta’s Genomics business delivers next‐generation sequencing (NGS), DNA synthesis, and molecular biology services.

Read More Five stocks we like better than Azenta SpaceX: Love the Company, But the Stock Is a Harder Call Ulta’s Growth Is Real, But So Are the Risks BWX Technologies Is Turning the AI Power Problem Into a Nuclear Growth Story Meta’s Earnings Drop Shows Wall Street Wants More Than Ad Growth Want to see what other hedge funds are holding AZTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Azenta, Inc. (NASDAQ:AZTA – Free Report).

Receive News & Ratings for Azenta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Azenta and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEADTRAN (NASDAQ:ADTN) Trading Down 7.5% After Analyst Downgrade

NEXT HEADLINE »Spyre Therapeutics (NASDAQ:SYRE) Price Target Raised to $130.00 at Wedbush

Azenta, Inc. (AZTA) Q3 2026 Earnings Call Transcript

, /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the third quarter ended June 30, 2026.

The results of B Medical Systems are reported as discontinued operations and reflected in total diluted EPS. The Company entered into a definitive agreement to sell the business during fiscal 2025, and the transaction closed on July 1, 2026, on the terms described in the Company's Current Report on Form 8-K filed on July 8, 2026.

Quarter Ended

Dollars in millions, except per share data

June 30,

March 31,

June 30,

Change

2026

2026

2025(1)

Prior Qtr

Prior Yr.

Revenue from Continuing Operations

$       161

$          145

$     144

11 %

12 %

Organic growth

9 %

Sample Management Solutions

$         88

$            81

$      78

9 %

14 %

Multiomics

$         73

$            64

$      66

14 %

10 %

Diluted EPS Continuing Operations

$      (0.03)

$        (3.41)

$   (0.01)

99 %

NM

Diluted EPS Total

$       0.05

$        (3.49)

$   (1.05)

NM

NM

Non-GAAP Diluted EPS Continuing Operations

$       0.16

$        (0.04)

$    0.17

NM

(6) %

Adjusted EBITDA - Continuing Operations

$          18

$              8

$      17

NM

6 %

Adjusted EBITDA Margin - Continuing Operations

11.4 %

5.4 %

12.1 %

(1)  Reflects revisions for an immaterial classification error among cost of revenue, research and development expenses, and selling, general and administrative expenses, and other immaterial
      adjustments, as further described in the Annual Report on Form 10-K for the fiscal year ended September 30, 2025.

Management Comments
"Despite an uneven and challenging market backdrop, our third quarter results exceeded our expectations, with continued strength in our recurring revenue businesses, and a modest improvement in Multiomics in North America," said John Marotta, President and Chief Executive Officer. "While these results represent an encouraging step forward, our turnaround continues, and we remain focused on executing against our strategic priorities."

Third Quarter Fiscal 2026 Results - Continuing Operations

Revenue was $161 million, up 12% year over year. Organic revenue, which excludes a 1-percentage point impact from foreign exchange and a 3-percentage point impact from the acquisition of UK Biocentre Limited, was up 9% year over year, reflecting higher revenue in Sample Management Solutions and Multiomics. Sample Management Solutions revenue was $88 million, up 14% year over year. Organic revenue, which excludes the impact from foreign exchange and the contribution from the acquisition of UK Biocentre Limited, was up 9%, mainly driven by higher revenue in Sample Repository Solutions and Consumables and Instruments, partially offset by lower revenue in Automated Stores. Multiomics revenue was $73 million, up 10% year over year. Organic revenue, which excludes the impact from foreign exchange, was up 8% year over year, primarily driven by higher revenue in Next Generation Sequencing and Gene Synthesis, partially offset by lower Sanger Sequencing revenue. Summary of GAAP Earnings Results - Continuing Operations

Operating loss was $4.2 million. Operating margin was (2.6%), down 131 basis points year over year. Gross margin was 44.9%, a decrease of 130 basis points year over year, primarily driven by unfavorable fixed-cost absorption associated with lower sales volumes in certain areas of the portfolio as well as costs related to quality remediation and rework activities in Automated Stores. These impacts were partially offset by improved operating leverage and the benefits of ongoing cost initiatives. Operating expenses in the quarter were $77 million, up 12% year-over-year, driven by higher research and development expenses and higher selling, general and administrative expenses, partially offset by lower restructuring and transformation charges. Total other income included $4 million of net interest income, versus $5 million in the prior year period. Diluted EPS from continuing operations was ($0.03) compared to ($0.01) in the third quarter of fiscal year 2025. Diluted EPS from discontinued operations was $0.09, compared to ($1.04) a year ago. Total diluted EPS was $0.05, compared to ($1.05) a year ago. Summary of Non-GAAP Earnings Results - Continuing Operations

Adjusted operating income was $4.7 million. Adjusted operating margin was 2.9%, a decrease of 180 basis points year over year. Adjusted gross margin was 46.2%, down 140 basis points compared to the third quarter of fiscal 2025, primarily driven by unfavorable fixed-cost absorption associated with lower sales volumes in certain areas of the portfolio as well as costs related to quality remediation and rework activities in Automated Stores. These impacts were partially offset by improved operating leverage and the benefits of ongoing cost initiatives. Adjusted operating expenses in the quarter were $70 million, up 13% year over year, driven by higher selling, general and administrative expenses and higher research and development expenses. Adjusted EBITDA was $18.5 million, and Adjusted EBITDA margin was 11.4%, a decrease of 60 basis points year over year. Non-GAAP Diluted EPS was $0.16, compared to $0.17 one year ago. Cash and Liquidity as of June 30, 2026

The Company ended the quarter with a total balance of cash, cash equivalents, restricted cash and marketable securities of $529 million. Operating cash flow was $1 million in the quarter. Capital expenditures were $7 million, and free cash flow (cash flow from operations less capital expenditures) was negative $5 million. Share Repurchase Program Update

On December 8, 2025, our Board of Directors approved a share repurchase program authorizing the repurchase of up to $250 million of our common stock through December 31, 2028, or the 2025 Repurchase Program. Repurchases under the 2025 Repurchase Program may be made in the open market or through privately negotiated transactions (including under an accelerated share repurchase agreement), or by other means, including through the use of trading plans intended to qualify under Rule 10b5-1 under the Exchange Act, subject to market and business conditions, legal requirements, and other factors. As of June 30, 2026, the Company repurchased 2.3 million shares of common stock for $50.0 million (excluding fees, commissions, and excise tax) pursuant to the 2025 Repurchase Program. All shares of common stock repurchased under the 2025 Repurchase Program have been retired. Fourth Quarter Fiscal 2026 Guidance - Continuing Operations

Total organic revenue, which excludes the impact of foreign exchange and the contribution from the acquisition of UK Biocentre Limited, is expected to decline approximately in the low single digits relative to the fourth quarter of fiscal 2025 Adjusted EBITDA is expected to range approximately between $20 million and $23 million Full Year Fiscal 2026 Guidance - Continuing Operations

The Company now expects total reported revenue from continuing operations to range approximately between $613 to $618 million, compared to prior guidance of $603 to $621 million for the fiscal year ending September 30, 2026.

Total organic revenue, which excludes the impact of foreign exchange and the contribution from the acquisition of UK Biocentre Limited, is now expected to range approximately between flat to up 1%, compared to prior guidance of down 2% to up 1% relative to fiscal 2025. Organic revenue for Sample Management Solutions is expected to grow low-single-digits, consistent with prior guidance. Organic revenue for Multiomics is now expected to range approximately between down 1% to flat, compared to prior guidance of down mid-single-digits. Adjusted EBITDA is expected to be in the range of $59 million to $62 million, including an anticipated impact of approximately 30 basis points of margin dilution from the UK Biocentre acquisition. Free cash flow (cash flow from operations less capital expenditures) is expected to improve approximately 10% to 15% year-over-year, consistent with prior guidance. Azenta does not provide forward-looking guidance on a GAAP basis for the measures on which it provides forward-looking non-GAAP guidance as the Company is unable to provide a quantitative reconciliation of forward-looking non-GAAP measures to the most directly comparable forward-looking GAAP measure, without unreasonable effort, because of the inherent difficulty in accurately forecasting the occurrence and financial impact of the various adjusting items necessary for such reconciliations that have not yet occurred, are dependent on various factors, are out of the Company's control, or cannot be reasonably predicted. Such adjustments include, but are not limited to, transformation costs, restructuring charges, costs related to acquisitions and divestitures, governance-related matters, goodwill and intangible impairments, stock-based compensation, and other gains and charges that are not representative of the normal operations of the business.

Conference Call and Webcast
Azenta management will webcast its third quarter fiscal 2026 earnings conference call on August 5, 2026 at 8:30 a.m. Eastern Time. During the call, Company management will respond to questions concerning, but not limited to, the Company's financial performance, business conditions and industry outlook. Management's responses could contain information that has not been previously disclosed.

The call will be broadcast live over the Internet and, together with presentation materials and supplemental information referenced on the call, will be hosted at the Investor Relations section of Azenta's website at https://investors.azenta.com/events. The supplemental information is being posted at the time of this earnings release, and the presentation materials will be posted ahead of the earnings call. A replay of the webcast will be archived on the website for convenient on-demand access.

Regulation G – Use of Non-GAAP Financial Measures
This release includes non-GAAP financial measures, including organic revenue, adjusted gross profit and margin, adjusted operating income, expenses and margin, EBITDA, Adjusted EBITDA and Adjusted EBITDA margin, non-GAAP net income, non-GAAP diluted EPS and free cash flow. Management believes these measures give investors additional insight into the results of business operations, improve period-to-period comparability and facilitate comparison with peers. Management uses these measures to evaluate business performance and uses organic revenue (referred to as Core Revenue in the Company's proxy statement), Adjusted EBITDA and free cash flow in determining compensation under the Company's annual incentive plan. They are not presented in accordance with, and are not a substitute for, U.S. generally accepted accounting principles, or GAAP, should always be considered together with the most directly comparable GAAP measures, and may not be comparable to similarly titled measures used by other companies. These measures are presented on a continuing operations basis, except free cash flow, which is presented on a total company basis inclusive of B Medical Systems. Non-GAAP diluted EPS does not exclude stock-based compensation; the Company separately presents non-GAAP adjusted net income excluding stock-based compensation. Reconciliations to the most directly comparable GAAP measures, and descriptions of the adjustments, are included at the end of this release under "Notes on Non-GAAP Financial Measures." Certain amounts may not sum due to rounding, and all percentages are calculated using unrounded amounts.

"Safe Harbor Statement" under Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended
Some statements in this release are forward-looking statements made under Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are neither promises nor guarantees but involve risks and uncertainties, both known and unknown, that could cause Azenta's actual financial and business results to differ materially from those expressed or implied by such statements. They are based on the facts and assumptions known to management at the time they are made. Forward looking statements include, but are not limited to, statements regarding the Company's guidance and outlook for fiscal year 2026, including revenue, organic revenue growth, earnings, Adjusted EBITDA margin and free cash flow expectations; expectations regarding the timing, execution and benefits of operational, commercial and organizational transformation initiatives; anticipated productivity improvements and cost actions; expectations regarding demand trends and end market conditions; statements regarding the Company's long range plan and multi-year financial targets, including the extension of the long range plan timeline to 2029.

Factors that could cause actual results to differ materially from those expressed or implied by forward looking statements include, but are not limited to: the Company's ability to execute on and realize the expected benefits from its transformation and operational improvement initiatives; changes in customer demand, purchasing behavior or funding conditions in the markets the Company serves; macroeconomic, geopolitical or regulatory developments; the impact of foreign currency fluctuations; the Company's ability to effectively manage costs, improve productivity and achieve anticipated margin improvements; supply chain disruptions; competitive dynamics; the ability of customers to meet payment obligations; risks relating to the collectability and timely repayment of the $35 million secured vendor loan extended to the buyer in connection with the B Medical Systems divestiture, including the buyer's ability to obtain permanent financing, the sufficiency of the collateral securing the loan, and the potential for an associated charge or impairment; and other risks and uncertainties described in the Company's filings with the Securities and Exchange Commission, including but not limited to its Annual Report on Form 10 K, Quarterly Reports on Form 10 Q and Current Reports on Form 8 K. Because forward looking statements relate to future events and are based on current expectations, they are inherently subject to significant uncertainties, particularly with respect to projections and assumptions extending over multiple years. As a result, actual outcomes may differ materially from those projected.

Azenta expressly disclaims any obligation or undertaking to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

About Azenta Life Sciences

 Azenta, Inc. (Nasdaq: AZTA) is a leading provider of life sciences solutions worldwide, enabling life science organizations around the world to bring impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and multiomics services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. Our global team delivers and supports these products and services through our industry-leading brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, and Barkey.

Azenta is headquartered in Burlington, Massachusetts, with operations in North America, Europe, and Asia. For more information, please visit www.azenta.com.

AZENTA INVESTOR CONTACTS:

Yvonne Perron
Vice President, Financial Planning & Analysis and Investor Relations
[email protected]

Maria Isabel Cuartas
Manager Investor Relations
[email protected]

AZENTA, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited)

(In thousands, except per share data)

Three Months Ended

June 30,

Nine Months Ended

June 30,

2026

2025

2026

2025

Revenue

Products

$       41,259

$       39,387

$      119,985

$      125,169

Services

119,919

104,468

334,630

309,460

Total revenue

161,178

143,855

454,615

434,629

Cost of revenue

Products

25,018

19,572

71,889

68,607

Services

63,804

57,879

184,629

168,016

Total cost of revenue

88,822

77,451

256,518

236,623

Gross profit

72,356

66,404

198,097

198,006

Operating expenses

Research and development

8,853

7,417

27,475

22,132

Selling, general and administrative

67,168

60,083

195,666

199,854

Impairment of goodwill and intangible assets

—

—

149,083

—

Restructuring charges

513

754

3,078

4,765

Total operating expenses

76,534

68,254

375,302

226,751

Operating loss

(4,178)

(1,850)

(177,205)

(28,745)

Other income (expense)

Interest income, net

3,825

4,973

13,310

13,760

Other income (expense), net

1,199

(820)

5,337

1,542

Income (loss) from continuing operations before income taxes

846

2,303

(158,558)

(13,443)

Income tax expense

2,375

2,635

5,182

13,752

Loss from continuing operations

(1,529)

(332)

(163,740)

(27,195)

Income (loss) from discontinued operations, net of tax

3,985

(47,655)

(10,034)

(79,445)

Net income (loss)

$         2,456

$      (47,987)

$     (173,774)

$     (106,640)

Basic net income (loss) per share:

Loss from continuing operations

$         (0.03)

$         (0.01)

$         (3.58)

$         (0.59)

Income (loss) from discontinued operations, net of tax

$          0.09

$         (1.04)

$         (0.22)

$         (1.74)

Basic net income (loss) per share

$          0.05

$         (1.05)

$         (3.80)

$         (2.33)

Diluted net income (loss) per share:

Loss from continuing operations

$         (0.03)

$         (0.01)

$         (3.58)

$         (0.59)

Income (loss) from discontinued operations, net of tax

$          0.09

$         (1.04)

$         (0.22)

$         (1.74)

Diluted net income (loss) per share

$          0.05

$         (1.05)

$         (3.80)

$         (2.33)

Weighted average shares used in computing net income (loss) per share:

Basic

45,286

45,780

45,759

45,712

Diluted

45,286

45,780

45,759

45,712

AZENTA, INC.

CONSOLIDATED BALANCE SHEETS

(unaudited)

(In thousands, except share and per share data)

June 30,
2026

September 30,
2025

Assets

Current assets

Cash and cash equivalents

$        189,654

$        279,783

Short-term marketable securities

136,143

61,137

Accounts receivable, net of allowance for expected credit losses ($3,953 and $4,649, respectively)

143,675

142,181

Inventories

79,082

74,956

Short-term restricted cash

2,414

2,359

Refundable income taxes

5,846

9,728

Prepaid expenses and other current assets

53,150

64,660

Current assets held for sale

71,387

73,535

Total current assets

681,351

708,339

Property, plant and equipment, net

172,427

153,954

Long-term marketable securities

196,087

201,585

Long-term deferred tax assets

494

726

Operating lease right-of-use assets

61,421

54,048

Goodwill

547,457

702,395

Intangible assets, net

85,688

101,814

Long-term income taxes receivable

45,600

45,600

Other assets

8,997

6,115

Noncurrent assets held for sale

76,689

85,006

Total assets

$      1,876,211

$      2,059,582

Liabilities and stockholders' equity

Current liabilities

Accounts payable

$         39,381

$         37,722

Deferred revenue

36,041

31,569

Derivative liability

28,435

33,420

Accrued warranty and retrofit costs

4,047

4,713

Accrued compensation and benefits

30,965

35,799

Customer deposits

35,355

26,499

Accrued income taxes payable

6,775

9,416

Deposit received for the sale of B Medical Systems business

28,000

—

Accrued expenses and other current liabilities

34,249

30,268

Current liabilities held for sale

29,326

28,268

Total current liabilities

272,574

237,674

Long-term deferred tax liabilities

15,836

18,245

Long-term operating lease liabilities

53,967

51,244

Other long-term liabilities

10,725

11,142

Noncurrent liabilities held for sale

12,980

14,291

Total liabilities

366,082

332,596

Stockholders' equity

Preferred stock, $0.01 par value - 1,000,000 shares authorized, no shares issued or outstanding

—

—

Common stock, $0.01 par value - 125,000,000 shares authorized, 57,226,616 shares issued and 43,764,747
shares outstanding at June 30, 2026; 59,320,848 shares issued and 45,858,979 shares outstanding at
September 30, 2025

572

594

Additional paid-in capital

493,071

529,605

Accumulated other comprehensive loss

(28,740)

(22,213)

Treasury stock, at cost - 13,461,869 shares at June 30, 2026 and September 30, 2025

(200,956)

(200,956)

Retained earnings

1,246,182

1,419,956

Total stockholders' equity

1,510,129

1,726,986

Total liabilities and stockholders' equity

$      1,876,211

$      2,059,582

AZENTA, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited)

(In thousands)

Nine Months Ended June 30,

2026

2025

Cash flows from operating activities

Net loss

$      (173,774)

$      (106,640)

Adjustments to reconcile net loss to net cash provided by operating activities:

Depreciation and amortization

41,230

46,775

Impairment of goodwill and intangible assets

149,083

—

Non-cash gain from settlement of preexisting contractual relationship

(3,858)

—

Loss on assets held for sale

9,491

92,706

Inventory write-downs and other non-cash items

1,301

3,866

Stock-based compensation

15,232

16,716

Amortization and accretion on marketable securities

(1,088)

(1,318)

Deferred income taxes

(3,563)

(20,385)

Loss on disposals of property, plant and equipment

14

759

Changes in operating assets and liabilities:

Accounts receivable

4,073

38,799

Inventories

(9,501)

(9,998)

Accounts payable

(655)

(365)

Deferred revenue

1,986

7,156

Accrued warranty and retrofit costs

84

38

Accrued compensation and tax withholdings

(3,816)

3,604

Accrued restructuring costs

26

(51)

Other assets and liabilities

9,540

(1,651)

Net cash provided by operating activities

35,805

70,011

Cash flows from investing activities

Purchases of property, plant and equipment

(20,234)

(25,997)

Purchases of marketable securities

(365,358)

(312,990)

Sales and maturities of marketable securities

295,489

242,527

Acquisition of UK Biocentre, net of cash acquired

(11,150)

—

Proceeds from other investment

—

2,130

Net investment hedge settlement

—

3,043

Deposit received for the sale of B Medical Systems business

28,000

—

Net cash used in investing activities

(73,253)

(91,287)

Cash flows from financing activities

Proceeds from issuance of common stock

1,178

1,553

Payments of finance leases

(583)

(585)

Withholding tax payments on net share settlements on equity awards

(2,521)

—

Excise tax payment for settled share repurchases

—

(11,376)

Share repurchases

(50,046)

—

Net cash used in financing activities

(51,972)

(10,408)

Effects of exchange rate changes on cash, cash equivalents and restricted cash

(2,594)

4,510

Net decrease in cash, cash equivalents and restricted cash

(92,014)

(27,174)

Cash, cash equivalents and restricted cash, beginning of period

296,685

320,990

Cash, cash equivalents and restricted cash, end of period

$       204,671

$       293,816

Supplemental disclosures:

Cash paid for income taxes, net

$         7,017

$         2,243

Purchases of property, plant and equipment included in accounts payable and accrued expenses

$         6,978

$         4,652

Reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheets

June 30,
2026

September 30,
2025

Cash and cash equivalents of continuing operations

$       189,654

$       279,783

Cash included in current assets held for sale

8,363

13,206

Short-term restricted cash

2,414

2,359

Long-term restricted cash included in other assets

4,240

1,337

Total cash, cash equivalents and restricted cash shown in the condensed consolidated statements of cash flows

$       204,671

$       296,685

Notes on Non-GAAP Financial Measures - Continuing Operations
Non-GAAP financial measures are used in addition to and in conjunction with results presented in accordance with GAAP and should not be relied upon to the exclusion of GAAP financial measures. Management adjusts the GAAP results for the impact of amortization of intangible assets, restructuring charges, purchase price accounting adjustments and charges related to M&A, costs related to the Company's business transformation initiatives and share repurchases to provide investors better perspective on the results of operations which the Company believes is more comparable to the similar analysis provided by its peers. Management also excludes special charges and gains, such as impairment losses, gains and losses from the sale of assets, certain tax benefits and charges, as well as other gains and charges that are not representative of the normal operations of the business. Management strongly encourages investors to review our financial statements and publicly filed reports in their entirety and not rely on any single measure.

Quarter Ended

June 30, 2026

March 31, 2026

June 30, 2025(*)

Amounts in thousands, except per share data

$

per diluted
share

$

per diluted
share

$

per diluted
share

Net loss from continuing operations

$    (1,529)

$     (0.03)

$             (157,021)

$     (3.41)

$    (332)

$     (0.01)

Adjustments:

Amortization of completed technology

2,082

0.05

2,076

0.05

2,068

0.05

Amortization of other intangible assets

3,616

0.08

3,563

0.08

4,123

0.09

Transformation costs(1)

272

0.01

440

0.01

1,542

0.03

Restructuring charges

513

0.01

1,422

0.03

754

0.02

Impairment of goodwill and intangible assets(2)

—

—

149,083

3.24

—

—

Merger and acquisition costs(3)

2,248

0.05

2,175

0.05

58

0.00

Non-recurring other adjustments(4)

—

0.00

(3,858)

(0.08)

38

0.00

Purchase accounting adjustments

154

0.00

—

—

—

—

Tax effect of adjustments

(198)

0.00

331

0.01

(534)

(0.01)

Other adjustments

—

—

13

0.00

—

—

Non-GAAP adjusted net income (loss) from continuing operations

$     7,158

$      0.16

$ (1,776)

$     (0.04)

$   7,717

$      0.17

Stock-based compensation, pre-tax

4,692

0.10

6,268

0.14

3,045

0.07

Tax rate

13 %

—

13 %

—

17 %

—

Stock-based compensation, net of tax

4,082

0.09

5,453

0.12

2,536

0.06

Non-GAAP adjusted net income excluding stock-based compensation - continuing operations

$   11,240

$      0.25

$   3,677

$      0.08

$ 10,253

$      0.22

Shares used in computing non-GAAP diluted net income per share

45,286

46,063

45,780

Nine Months Ended

June 30, 2026

June 30, 2025(*)

Amounts in thousands, except per share data

$

per diluted
share

$

per diluted
share

Net loss from continuing operations

$   (163,740)

$         (3.58)

$    (27,195)

$         (0.59)

Adjustments:

Amortization of completed technology

6,017

0.13

5,876

0.13

Amortization of other intangible assets

10,730

0.23

12,499

0.27

Transformation costs(1)

1,913

0.04

9,771

0.21

Restructuring charges

3,078

0.07

4,765

0.10

Impairment of goodwill and intangible assets(2)

149,083

3.26

—

—

Merger and acquisition costs(3)

4,436

0.10

2,316

0.05

Non-recurring other adjustments(4)

(3,858)

(0.08)

(2,097)

(0.05)

Purchase accounting adjustment

154

0.00

—

—

Tax adjustments(5)

—

—

7,300

0.16

Tax effect of adjustments

1,704

0.04

571

0.01

Other adjustments

22

0.00

—

—

Non-GAAP adjusted net income from continuing operations

$        9,539

$          0.21

$     13,806

$          0.30

Stock-based compensation, pre-tax

14,822

0.32

15,949

0.35

Tax rate

13 %

—

17 %

—

Stock-based compensation, net of tax

12,895

0.28

13,238

0.29

Non-GAAP adjusted net income excluding stock-based compensation - continuing operations

$       22,434

$          0.49

$     27,044

$          0.59

Shares used in computing non-GAAP diluted net income per share

45,759

45,712

(*) 

See footnote (1) on Page 1.

(1) 

Transformation costs represent expenses associated with discrete strategic initiatives undertaken to simplify, standardize, streamline, and optimize the Company's operations, processes, and systems. These initiatives are intended to generate long-term operational efficiencies and productivity improvements and do not meet the definition of restructuring charges. Transformation costs primarily include asset write-downs associated with technology changes, inventory write-downs related to restructuring activities, and third-party consulting costs incurred to support process and systems redesign efforts.

(2) 

Represents a non-cash goodwill impairment charge recognized in the second quarter of fiscal 2026 as a result of the Company's quantitative goodwill impairment analysis as of March 31, 2026, including $112.4 million for the Multiomics reporting unit and $36.6 million for the Sample Management Solutions reporting unit.

(3) 

Merger and acquisition costs consist primarily of legal, accounting, valuation, and strategic advisory fees incurred in connection with acquisition and integration activities.

(4) 

The Company recognized $3.9 million non-cash gain from the settlement of the pre-existing contractual relationship with UK Biocentre Limited in the second quarter of fiscal 2026. The Company received $2.1 million of cash proceeds from a cost method investment which had no cost basis in the second quarter of fiscal 2025. These are non-recurring and non-operational adjustments.

(5) 

Tax adjustments for the nine months ended June 30, 2025 are primarily driven by tax expenses related to a one-time repatriation of historical earnings from China.

Quarter Ended

Nine Months Ended

Dollars in thousands

June 30, 2026

March 31, 2026

June 30, 2025(*)

June 30, 2026

June 30, 2025(*)

GAAP net loss

$       2,456

$  (160,798)

$    (47,987)

$   (173,774)

$   (106,640)

Less: Loss from discontinued operations

3,985

(3,777)

(47,655)

(10,034)

(79,445)

GAAP net loss from continuing operations

(1,529)

(157,021)

(332)

(163,740)

(27,195)

Adjustments:

Interest income, net

(3,825)

(4,387)

(4,973)

(13,310)

(13,760)

Income tax expense

2,375

(323)

2,635

5,182

13,752

Depreciation

7,861

8,338

8,399

24,406

23,695

Amortization of completed technology

2,082

2,076

2,068

6,017

5,876

Amortization of other intangible assets

3,616

3,563

4,123

10,730

12,499

Earnings before interest, taxes, depreciation and amortization - Continuing operations

$      10,580

$  (147,754)

$      11,920

$   (130,715)

$      14,867

Quarter Ended

Nine Months Ended

Dollars in thousands

June 30, 2026

March 31, 2026

June 30, 2025(*)

June 30, 2026

June 30, 2025(*)

Earnings before interest, taxes, depreciation and amortization - Continuing operations

$      10,580

$   (147,754)

$      11,920

$   (130,715)

$      14,867

Adjustments:

Stock-based compensation

4,692

6,268

3,045

14,822

15,949

Restructuring charges

513

1,422

754

3,078

4,765

Impairment of goodwill and intangible assets(1)

—

149,083

—

149,083

—

Merger and acquisition costs(2)

2,248

2,175

58

4,436

2,316

Transformation costs(3)

272

440

1,542

1,913

9,771

Non-recurring other adjustments(4)

—

(3,858)

38

(3,858)

(2,097)

Purchase accounting adjustment

154

—

—

154

—

Adjusted earnings before interest, taxes, depreciation and amortization - Continuing operations

$      18,459

$       7,776

$      17,357

$      38,913

$      45,571

(*) 

See footnote (1) on Page 1.

(1) 

Represents a non-cash goodwill impairment charge recognized in the second quarter of fiscal 2026 as a result of the Company's quantitative goodwill impairment analysis as of March 31, 2026, including $112.4 million for the Multiomics reporting unit and $36.6 million for the Sample Management Solutions reporting unit.

(2) 

Merger and acquisition costs consist primarily of legal, accounting, valuation, and strategic advisory fees incurred in connection with acquisition and integration activities.

(3) 

Transformation costs represent expenses associated with discrete strategic initiatives undertaken to simplify, standardize, streamline, and optimize the Company's operations, processes, and systems. These initiatives are intended to generate long-term operational efficiencies and productivity improvements and do not meet the definition of restructuring charges. Transformation costs primarily include asset write-downs associated with technology changes, inventory write-downs related to restructuring activities, and third-party consulting costs incurred to support process and systems redesign efforts.

(4) 

The Company recognized $3.9 million non-cash gain from the settlement of the pre-existing contractual relationship with UK Biocentre Limited in the second quarter of fiscal 2026. The Company received $2.1 million of cash proceeds from a cost method investment which had no cost basis in the second quarter of fiscal 2025. These are non-recurring and non-operational adjustments.

Quarter Ended

Dollars in thousands

June 30, 2026

March 31, 2026

June 30, 2025(*)

GAAP gross profit

$   72,356

44.9 %

$   62,035

42.8 %

$   66,404

46.2 %

Adjustments:

Amortization of completed technology

2,082

1.3 %

2,076

1.4 %

2,068

1.4 %

Other Adjustments

—

— %

—

— %

25

0.0 %

Non-GAAP adjusted gross profit

$   74,438

46.2 %

$   64,111

44.3 %

$   68,497

47.6 %

Nine Months Ended

Dollars in thousands

June 30, 2026

June 30, 2025(*)

GAAP gross profit

$        198,097

43.6 %

$        198,006

45.6 %

Adjustments:

Amortization of completed technology

6,017

1.3 %

5,876

1.4 %

Transformation costs(1)

—

— %

51

0.0 %

Other Adjustments

—

— %

25

0.0 %

Non-GAAP adjusted gross profit

$        204,114

44.9 %

$        203,958

46.9 %

(*) 

See footnote (1) on Page 1.

(1) 

Transformation costs represent expenses associated with discrete strategic initiatives undertaken to simplify, standardize, streamline, and optimize the Company's operations, processes, and systems. These initiatives are intended to generate long-term operational efficiencies and productivity improvements and do not meet the definition of restructuring charges. Transformation costs primarily include asset write-downs associated with technology changes, inventory write-downs related to restructuring activities, and third-party consulting costs incurred to support process and systems redesign efforts.

Sample Management Solutions

Multiomics

Quarter Ended

Quarter Ended

Dollars in thousands

June 30,
2026

March 31,
2026

June 30, 2025(*)

June 30,
2026

March 31,
2026

June 30, 2025(*)

GAAP gross profit

$     39,126

44.3 %

$     37,084

45.7 %

$     40,180

51.8 %

$     33,230

45.6 %

$     24,951

39.2 %

$     26,224

39.6 %

Adjustments:

Amortization of completed technology

1,393

1.6 %

1,389

1.7 %

1,208

1.6 %

689

0.9 %

687

1.1 %

860

1.3 %

Other Adjustments

—

— %

—

— %

25

0.0 %

—

— %

—

— %

—

— %

Non-GAAP adjusted gross profit

$     40,519

45.9 %

$     38,473

47.4 %

$     41,413

53.4 %

$     33,919

46.5 %

$     25,638

40.2 %

$     27,084

40.9 %

Segment Total

Quarter Ended

Dollars in thousands

June 30,
2026

March 31,
2026

June 30, 2025(*)

GAAP gross profit

$        72,356

44.9 %

$        62,035

42.8 %

$        66,404

46.2 %

Adjustments:

Amortization of completed technology

2,082

1.3 %

2,076

1.4 %

2,068

1.4 %

Other Adjustments

—

— %

—

— %

25

0.0 %

Non-GAAP adjusted gross profit

$        74,438

46.2 %

$        64,111

44.3 %

$        68,497

47.6 %

Sample Management Solutions

Multiomics

Nine Months Ended

Nine Months Ended

Dollars in thousands

June 30, 2026

June 30, 2025(*)

June 30, 2026

June 30, 2025(*)

GAAP gross profit

$  111,993

44.7 %

$  115,471

48.4 %

$   86,104

42.2 %

$   82,535

42.1 %

Adjustments:

Amortization of completed technology

3,958

1.6 %

3,296

1.4 %

2,059

1.0 %

2,580

1.3 %

Transformation costs(1)

—

— %

51

0.0 %

—

— %

—

— %

Other Adjustments

—

— %

25

0.0 %

$       —

— %

$       —

— %

Non-GAAP adjusted gross profit

115,951

46.2 %

118,843

49.8 %

$   88,163

43.3 %

$   85,115

43.4 %

Segment Total

Nine Months Ended

Dollars in thousands

June 30, 2026

June 30, 2025(*)

GAAP gross profit

$        198,097

43.6 %

$        198,006

45.6 %

Adjustments:

Amortization of completed technology

6,017

1.3 %

5,876

1.4 %

Transformation costs(1)

—

— %

51

0.0 %

Other Adjustments

—

— %

$               25

0.0 %

Non-GAAP adjusted gross profit

204,114

44.9 %

$        203,958

46.9 %

(*) 

See footnote (1) on Page 1.

(1) 

Transformation costs represent expenses associated with discrete strategic initiatives undertaken to simplify, standardize, streamline, and optimize the Company's operations, processes, and systems. These initiatives are intended to generate long-term operational efficiencies and productivity improvements and do not meet the definition of restructuring charges. Transformation costs primarily include asset write-downs associated with technology changes, inventory write-downs related to restructuring activities, and third-party consulting costs incurred to support process and systems redesign efforts.

Total Segments

Corporate

Total

Quarter Ended

Quarter Ended

Quarter Ended

Dollars in thousands

June 30,
2026

March 31,
2026

June 30, 2025(*)

June 30,
2026

March 31,
2026

June 30, 2025(*)

June 30,
2026

March 31,
2026

June 30, 2025(*)

GAAP operating loss

$    2,051

$   (9,091)

$  4,505

$   (6,229)

$ (156,699)

$   (6,355)

$   (4,178)

$         (165,790)

$   (1,850)

Adjustments:

Amortization of completed technology

2,082

2,076

2,068

—

—

—

2,082

2,076

2,068

Amortization of other intangible assets

49

—

—

3,567

3,563

4,123

3,616

3,563

4,123

Transformation costs(1)

56

55

168

216

385

1,374

272

440

1,542

Restructuring charges

—

—

—

513

1,422

754

513

1,422

754

Impairment of goodwill and intangible assets(2)

—

—

—

—

149,083

—

—

149,083

—

Merger and acquisition costs(3)

204

—

—

2,044

2,175

58

2,248

2,175

58

Purchase accounting and other adjustments

154

8

38

—

—

(5)

154

8

33

Non-GAAP adjusted operating income (loss)

$    4,596

$   (6,952)

$  6,779

$     111

$      (71)

$      (51)

$    4,707

$ (7,023)

$    6,728

Total Segments

Corporate

Total

Nine Months Ended

Nine Months Ended

Nine Months Ended

Dollars in thousands

June 30,
2026

June 30,
2025(*)

June 30,
2026

June 30,
2025(*)

June 30,
2026

June 30,
2025(*)

GAAP operating loss

$   (8,355)

$   (2,276)

$ (168,850)

$  (26,469)

$ (177,205)

$  (28,745)

Adjustments:

Amortization of completed technology

6,017

5,876

—

—

6,017

5,876

Amortization of other intangible assets

49

—

10,681

12,499

10,730

12,499

Transformation costs(1)

168

2,877

1,745

6,894

1,913

9,771

Restructuring charges

—

—

3,078

4,765

3,078

4,765

Impairment of goodwill and intangible assets(2)

—

—

149,083

—

149,083

—

Merger and acquisition costs(3)

204

—

4,232

2,316

4,436

2,316

Purchase accounting and other adjustments

175

40

—

(5)

175

35

Non-GAAP adjusted operating income (loss)

$   (1,742)

$    6,517

$       (31)

$        —

$   (1,773)

$    6,517

(*) 

See footnote (1) on Page 1.

(1) 

Transformation costs represent expenses associated with discrete strategic initiatives undertaken to simplify, standardize, streamline, and optimize the Company's operations, processes, and systems. These initiatives are intended to generate long-term operational efficiencies and productivity improvements and do not meet the definition of restructuring charges. Transformation costs primarily include asset write-downs associated with technology changes, inventory write-downs related to restructuring activities, and third-party consulting costs incurred to support process and systems redesign efforts.

(2) 

Represents non-cash goodwill impairment charges recognized in the second quarter of fiscal 2026 as a result of the Company's annual and interim impairment assessment, including $112.4 million for the Multiomics reporting unit and $36.6 million for the Sample Management Solutions reporting unit.

(3) 

Merger and acquisition costs consist primarily of legal, accounting, valuation, and strategic advisory fees incurred in connection with acquisition and integration activities.

Sample Management Solutions

Multiomics

Azenta Total

Quarter Ended

Quarter Ended

Quarter Ended

Dollars in millions

June 30,
2026

June 30,
2025

Change

June 30,
2026

June 30,
2025

Change

June 30,
2026

June 30,
2025

Change

Revenue

$      88

$      78

14 %

$      73

$      66

10 %

$     161

$     144

12 %

Acquisitions

(4)

—

(5) %

—

—

— %

(4)

—

(3) %

Currency exchange rates

(0)

—

(0) %

(1)

—

(2) %

(1)

—

(1) %

Organic revenue

$      84

$      78

9 %

$      72

$      66

8 %

$     156

$     144

9 %

Sample Management Solutions

Multiomics

Azenta Total

Nine Months Ended

Nine Months Ended

Nine Months Ended

Dollars in millions

June 30,
2026

June 30,
2025

Change

June 30,
2026

June 30,
2025

Change

June 30,
2026

June 30,
2025

Change

Revenue

$     251

$     239

5 %

$     204

$     196

4 %

$     455

$     435

5 %

Acquisitions

(5)

—

(2) %

—

—

— %

(5)

—

(1 %)

Currency exchange rates

(4)

—

(2) %

(4)

—

(2) %

(8)

—

(2) %

Organic revenue

$     242

$     239

1 %

$     200

$     196

2 %

$     442

$     435

2 %

SOURCE Azenta

, /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) will announce fiscal third quarter 2026 earnings which ended on June 30, 2026, on Tuesday, August 4, 2026, after the market closes.

The Company will host a conference call and live webcast to discuss its financial results the following day, Wednesday, August 5, 2026, at 8:30 a.m. Eastern Time. Analysts, investors and members of the media can access the live webcast via the Azenta website at https://investors.azenta.com/events. A replay will be available beginning at 8:30 a.m. ET on August 6, 2026.

About Azenta Life Sciences

Azenta, Inc. (Nasdaq: AZTA) is a leading provider of life sciences solutions worldwide, enabling impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and multiomics services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. Our global team delivers and supports these products and services through our industry-leading brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, and Barkey.

Azenta is headquartered in Burlington, MA, with operations in North America, Europe and Asia. For more information, please visit www.azenta.com.

INVESTOR CONTACTS:
Yvonne Perron
Vice President, Financial Planning & Analysis, and Investor Relations
[email protected]

Maria Isabel Cuartas
Manager Investor Relations
[email protected]

SOURCE Azenta

NEW YORK, May 18, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Azenta, Inc. (“Azenta” or the “Company”) (NASDAQ:AZTA) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws or other unlawful business practices.

[LEARN MORE ABOUT THE INVESTIGATION]

What Happened?

On May 5, 2026, Azenta reported its second quarter fiscal 2026 financial results and updated its full-year outlook. Among other things, the Company disclosed that its second quarter results “fell short” of expectations, reflecting “both execution gaps and a more cautious demand environment.” Azenta further disclosed that results were impacted by “costs related to Automated Stores rework” and that the Company recorded a $149 million non-cash goodwill impairment charge during the quarter. In addition, Azenta reduced its fiscal 2026 outlook, stating that organic revenue was now expected to range from down approximately 2% to up 1%, compared to prior guidance of 3% to 5% growth. The Company also reduced its adjusted EBITDA margin outlook and announced that it was extending the timeline for its long-range plan targets from 2028 to 2029. On this news, the price of Azenta shares declined by $6.23 per share, or approximately 25%, from $24.61 per share on May 5, 2026 to close at $18.38 on May 6, 2026.

What Should I Do?

At this stage, no lawsuit has been filed. The investigation is ongoing to determine whether claims may be brought under federal securities laws.

If you purchased or otherwise acquired Azenta securities, have information, or would like to learn more about this investigation, please contact Lauren Molinaro of Kirby McInerney LLP by email at [email protected], or fill out the contact form below, to discuss your rights or interests with respect to these matters at no cost.

[LEARN MORE ABOUT SECURITES CLASS ACTIONS]

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts
Kirby McInerney LLP        
Lauren Molinaro, Esq.
212-699-1171
https://www.kmllp.com
https://securitiesleadplaintiff.com/
[email protected]

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Azenta (AZTA) To Contact Him Directly To Discuss Their Options

If you purchased or acquired stock in Azenta and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Melissa Fortunato directly at (212) 355-4648.

Click here to participate in the action.

NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) --

What’s Happening:

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Azenta, Inc. (“Azenta” or the “Company”) (NASDAQ:AZTA) on behalf of Azenta stockholders. Our investigation concerns whether Azenta has violated the federal securities laws and/or engaged in other unlawful business practices. Investigation Details:

On May 5, 2026, Azenta announced its financial results for the second quarter of fiscal 2026 and revised its full-year guidance. Among other disclosures, the Company stated that its second quarter performance “fell short” of expectations, citing “both execution gaps and a more cautious demand environment.” Azenta also disclosed that the quarter’s results were affected by “costs related to Automated Stores rework” and that it had recorded a $149 million non-cash goodwill impairment charge during the quarter. Additionally, the Company lowered its fiscal 2026 outlook, stating that it now expected organic revenue to range from a decline of approximately 2% to growth of 1%, compared to its previous guidance of 3% to 5% growth. Azenta further reduced its adjusted EBITDA margin outlook and announced that it was extending the timeline for achieving its long-range plan targets from 2028 to 2029. Following this news, Azenta’s share price fell by $6.23 per share, or approximately 25%, declining from $24.61 per share on May 5, 2026 to close at $18.38 per share on May 6, 2026. Next Steps:

If you purchased or otherwise acquired Azenta shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at [email protected], by telephone at (212) 355-4648, or by filling out this contact form.  There is no cost or obligation to you. About Bragar Eagel & Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California. The firm represents individual and institutional investors in securities,
derivative, and commercial litigation as well as individuals in consumer protection and data privacy litigation. The firm has a nationwide practice and routinely handles cases in both federal and state courts. For more information about the firm, please visit www.bespc.com.  Attorney advertising.  Prior results do not guarantee similar outcomes.

Follow us for updates on LinkedIn and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn.

Contact Information:

Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Melissa Fortunato, Esq.
(212) 355-4648
[email protected]
www.bespc.com

Azenta, Inc. reaffirmed 3%-5% organic revenue growth and 300 basis points of margin expansion in February 2026 -- then disclosed a $149 million goodwill impairment and slashed guidance three months later May 21, 2026 09:00 ET  | Source: Levi & Korsinsky, LLP

NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- Investors in Azenta, Inc. (NASDAQ: AZTA) suffered significant losses after the Company disclosed a $149 million goodwill impairment in its Q2 FY 2026 results on May 5, 2026, alongside a $160.8 million net loss and a substantial reduction in its full-year outlook. Shareholders who lost money on their Azenta investment are encouraged to submit their information to Levi & Korsinsky. You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

During the Q1 2026 earnings call on February 4, 2026, CEO John Marotta told investors: "We are entering the year well positioned for continued success... I am confident in the path we are taking." On the same call, management reaffirmed full-year 2026 guidance of 3%-5% organic revenue growth and adjusted EBITDA margin expansion of approximately 300 basis points. CFO Laurence Flynn stated: "We remain confident that the strategic priorities outlined at Investor Day provide a clear roadmap to drive sustainable, profitable growth."

Three months later, on May 5, 2026, Azenta reported a $149 million goodwill impairment tied to its Multiomics segment, a $160.8 million net loss for the quarter, and reduced its FY 2026 revenue and margin guidance. The February 4 reaffirmation of full-year targets did not reference the goodwill impairment risk that was later reported in May.

If you purchased Azenta shares and suffered a loss, click here to discuss your legal rights with Levi & Korsinsky. You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

WHY LEVI & KORSINSKY -- Ranked in ISS Securities Class Action Services' Top 50 Report for seven consecutive years, Levi & Korsinsky, LLP is a nationally recognized leader in shareholder rights litigation. With a team of over 70 professionals, the firm has recovered hundreds of millions of dollars for investors.

Frequently Asked Questions About the AZTA Investigation

Q: Who is conducting the AZTA investigation? A: Levi & Korsinsky, LLP is investigating potential securities law violations on behalf of investors who purchased AZTA securities. The firm is nationally recognized, ranked in the ISS Top 50 for seven consecutive years, and has recovered hundreds of millions of dollars for aggrieved investors.

Q: Which statements are being investigated as potentially misleading? A: The investigation concerns whether Azenta made materially false or misleading statements regarding its full-year 2026 guidance, including the reaffirmation of 3%-5% organic revenue growth and approximately 300 basis points of margin expansion, while a $149 million goodwill impairment was pending. When the impairment and guidance reduction were disclosed, the stock declined significantly.

Q: Who is eligible to participate in the AZTA investigation? A: Investors who purchased AZTA stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.

Q: What do AZTA investors need to do right now? A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact Levi & Korsinsky for a free, no-obligation evaluation at [email protected] or (212) 363-7500. No immediate action is required to remain eligible to participate in the investigation.

Q: What if I already sold my AZTA shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought AZTA and sold at a loss may still participate in the investigation.

Q: What does it cost me to participate? A: Nothing. Securities investigations and any resulting actions are handled on a pure contingency basis. No upfront fees, no retainer, no out-of-pocket costs.

Q: Do I need to go to court or give testimony? A: No. Participating in the investigation does not require court appearances or depositions. If legal action is later pursued, the overwhelming majority of affected investors never appear in court either.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

Ed Korsinsky, Esq.

33 Whitehall Street, 27th Floor

New York, NY 10004

[email protected]

Tel: (212) 363-7500

Fax: (212) 363-7171

, /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced the publication of its annual Environmental, Social, & Governance ("ESG") report, demonstrating continued progress against its key ESG priorities. The report includes ESG data for the Company's fiscal year ended September 30, 2025.

The report offers a comprehensive overview of the Company's ESG approach, highlighting achievements across three core pillars:

Environmental Protection: We understand the broad scope of our operations and are committed to reducing our environmental impact while continuing to expand our business. Social Impact: We are committed to making a positive impact on society, particularly in the regions where we operate and serve our customers. Responsible Operations: Our products and services help enable our customers to have a significant positive impact on the world, and we are committed to ensuring the safety, quality, and reliability of our products and services. In 2025, we achieved key milestones in our ESG journey, including:

Disclosing our Scope 3 GHG emissions for the first time, establishing a value chain emissions baseline that sets the foundation for targeted reduction efforts and long-term climate action. Submitting near-term GHG reduction targets to the Science Based Targets initiative (SBTi) for validation, including a 45% absolute reduction in Scope 1 and 2 emissions and a 25% absolute reduction in Scope 3 emissions across key value chain categories by FY2033, from a FY2025 base year. Reducing our Scope 1 and 2 carbon footprint by approximately 40% compared to a FY2022 base year (market-based), while sourcing 72% of our electricity from renewable sources. Advancing sustainable innovation with products like the BioArc™ Ultra, providing our customers with cutting-edge solutions for large-scale, eco-friendly sample storage. Completing our second annual Global Well-being Week, offering employees programming across physical, financial, and mental well-being. Refreshing our Enterprise Risk Management (ERM) framework, with Board approval of updated risk assessment processes and clearer accountability across business units, strengthening our approach to enterprise and operational risk management. Expanding the Azenta Business System (ABS) across global operations, equipping teams with tools and capabilities to improve quality, reduce waste, and deliver better outcomes for customers. To learn more about Azenta's commitment to ESG efforts, view the report in full at https://investors.azenta.com/esg.

About Azenta Life Sciences

Azenta, Inc. (Nasdaq: AZTA) is a leading provider of life sciences solutions worldwide, enabling life science organizations around the world to bring impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and multiomics services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. Our global team delivers and supports these products and services through our industry-leading brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, and Barkey.

Azenta is headquartered in Burlington, MA, with operations in North America, Europe and Asia. For more information, please visit www.azenta.com.

"Safe Harbor Statement" under Section 21E of the Securities Exchange Act of 1934

This press release contains forward‑looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Forward‑looking statements are based on current assumptions, expectations, and beliefs and include, without limitation, statements regarding the Company's ESG strategy and priorities; anticipated reductions in greenhouse gas emissions, including Scope 1, 2, and 3 reduction targets; the Company's ability to source renewable energy; expectations regarding sustainable product innovation, including the BioArc™ Ultra platform; plans to expand the Azenta Business System (ABS) across global operations; and other statements that are not historical facts.

Forward‑looking statements are not guarantees of future performance, and actual results may differ materially due to a variety of risks and uncertainties. These risks include, but are not limited to: the Company's ability to achieve its greenhouse gas emission reduction targets on the anticipated timeline or at all; changes in the cost, availability, or reliability of renewable energy sources; evolving ESG‑related laws, regulations, and reporting standards, including potential changes to SEC climate disclosure rules; the availability and accuracy of data used to measure and report ESG metrics, including Scope 3 emissions; the ability to successfully implement operational improvement initiatives; changes in customer expectations regarding sustainability; general market, industry, regulatory, or economic conditions; and other factors described in the Company's filings with the Securities and Exchange Commission, including the "Risk Factors" section of the Company's most recent Annual Report on Form 10‑K and subsequent Quarterly Reports on Form 10‑Q.

Forward‑looking statements speak only as of the date of this release. Azenta undertakes no obligation to publicly update or revise any forward‑looking statements, whether as a result of new information, future developments, or otherwise, except as required by law.

INVESTOR CONTACTS:
Yvonne Perron
Vice President, Financial Planning & Analysis, and Investor Relations
[email protected]

María Isabel Cuartas
Manager Investor Relations
[email protected]

SOURCE Azenta

Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, continues its investigation on behalf of Azenta, Inc. (“Azenta” or the “Company”) (NASDAQ: AZTA) investors concerning the Company’s possible violations of the federal securities laws.

IF YOU ARE AN INVESTOR WHO LOST MONEY ON AZENTA, INC. (AZTA), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.

What Happened?

On May 5, 2026, Azenta released its second quarter 2026 financial results, missing consensus estimates in EPS and revenue due to “execution-related shortfalls within [the Company’s] control” as well as “a more cautious prolonged demand environment.” The Company also reported a $149 million goodwill impairment.

Additionally, Azenta reduced its 2026 outlook, stating that organic revenue was now expected to range from down approximately 2% to up 1%, compared to prior guidance of 3% to 5% growth. The Company also reduced its adjusted EBITDA margin outlook and announced that it was extending the timeline for its long-range plan targets from 2028 to 2029.

On this news, Azenta’s stock price fell $6.23, or 25.3%, to close at $18.38 per share on May 6, 2026, thereby injuring investors.

Contact Us To Participate or Learn More:

If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us.

Charles Linehan, Esq.
Glancy Prongay Wolke & Rotter LLP
1925 Century Park East, Suite 2100
Los Angeles, California 90067
Email: [email protected]
Telephone: 310-201-9150 (Toll-Free: 888-773-9224)
Visit our website at www.glancylaw.com.
Follow us for updates on LinkedIn, Twitter, or Facebook.

Whistleblower Notice

Persons with non-public information regarding Azenta should consider their options to aid the investigation or take advantage of the SEC Whistleblower Program. Under the program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Charles H. Linehan at 310-201-9150 or 888-773-9224 or email [email protected].

About Glancy Prongay Wolke & Rotter LLP

GPWR is a premier law firm with decades of experience representing investors and consumers in securities litigation and other complex class action litigation. Recognizing the firm’s recent successes, GPWR was named one of Law360’s Securities Groups of the Year and ranked second-highest in total investor recoveries by Institutional Shareholder Services Securities Class Action Services in 2025. GPWR’s lawyers have handled cases covering a wide spectrum of corporate misconduct and relating to nearly all industries and sectors. GPWR’s past successes have been widely covered by leading news and industry publications such as The Wall Street Journal, The Financial Times, Bloomberg Businessweek, Reuters, the Associated Press, Barron’s, Investor’s Business Daily, Forbes, and Money. Prior results do not guarantee a similar outcome.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260522237239/en/

The Law Offices of Frank R. Cruz continues its investigation of Azenta, Inc. (“Azenta” or the “Company”) (NASDAQ: AZTA) on behalf of investors concerning the Company’s possible violations of federal securities laws.

IF YOU ARE AN INVESTOR WHO LOST MONEY ON AZENTA, INC. (AZTA), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS.

What Is The Investigation About?

On May 5, 2026, Azenta released its second quarter 2026 financial results, missing consensus estimates in EPS and revenue due to “execution-related shortfalls within [the Company’s] control” as well as “a more cautious prolonged demand environment.” The Company also reported a $149 million goodwill impairment.

Additionally, Azenta reduced its 2026 outlook, stating that organic revenue was now expected to range from down approximately 2% to up 1%, compared to prior guidance of 3% to 5% growth. The Company also reduced its adjusted EBITDA margin outlook and announced that it was extending the timeline for its long-range plan targets from 2028 to 2029.

On this news, Azenta’s stock price fell $6.23, or 25.3%, to close at $18.38 per share on May 6, 2026, thereby injuring investors.

Contact Us To Participate or Learn More:

If you purchased Azenta securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:

The Law Offices of Frank R. Cruz,
2121 Avenue of the Stars, Suite 800,
Century City, California 90067
Call us at: 310-914-5007
Visit our website at: www.frankcruzlaw.com.
Email us at: [email protected]
Follow us for updates on Twitter at twitter.com/FRC_LAW.

If you inquire by email, please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260522116288/en/

New York, New York--(Newsfile Corp. - May 25, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Azenta, Inc. (NASDAQ: AZTA) ("Azenta, Inc.") concerning potential violations of the federal securities laws.

On February 4, 2026, CEO John Marotta told investors Azenta was "entering the year well positioned for continued success" and reaffirmed FY 2026 guidance of 3%-5% organic revenue growth with approximately 300 basis points of adjusted EBITDA margin expansion. On May 5, 2026, the Company reported Q2 FY 2026 results that included a $149 million goodwill impairment charge in its Multiomics segment. The resulting net loss of $160.8 million stood in stark contrast to the growth trajectory management had presented ninety days prior.

Alongside the impairment, Azenta reduced its full-year FY 2026 guidance -- trimming the revenue growth and margin expansion targets it had publicly reaffirmed in February. The gap between the Company's stated outlook and its reported results is now the subject of an investigation into potential securities law violations.

If you suffered a loss on your Azenta, Inc. securities and would like to explore a potential recovery under the federal securities laws, Learn More About the Investigation or contact Joseph E. Levi, Esq. via email at [email protected] or call (212)363-7500 to speak to our team of experienced shareholder advocates.

WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (212)363-7500
Fax: (212)363-7171

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/298723

Source: Levi & Korsinsky, LLP

Azenta, Inc. reaffirmed 3%-5% organic revenue growth and 300 basis points of margin expansion in February 2026 -- then cut both targets three months later after recording a $149 million goodwill impairment.

, /PRNewswire/ -- Shareholders who purchased Azenta, Inc. (NASDAQ: AZTA) stock lost significant value after the Company slashed its FY 2026 guidance on May 5, 2026 -- reversing projections it had publicly reaffirmed just three months earlier. Those who suffered losses are encouraged to submit their information to Levi & Korsinsky. You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

On February 4, 2026, during the Q1 FY 2026 earnings call, CEO John Marotta told investors: "We are reaffirming our guidance for fiscal 2026 with organic revenue growth expected in the range of 3% to 5%…we are also reaffirming our target of approximately 300 basis points of year-over-year adjusted EBITDA margin expansion." CFO Laurence Flynn added that the Company's strategic priorities provided "a clear road map to drive sustainable, profitable growth." Neither executive disclosed any risk of the goodwill impairment that followed.

On May 5, 2026, Azenta reported Q2 FY 2026 results that included a $149 million goodwill impairment and a $160.8 million net loss. The Company simultaneously reduced its full-year revenue and margin guidance. The gap between the February reaffirmation and the May revision raises the question of what conditions had changed -- and when management became aware of them.

If you lost money on your Azenta investment, click here to discuss your legal rights with Levi & Korsinsky. You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

Levi & Korsinsky, LLP | Top 50 Securities Firm | (212) 363-7500 | www.zlk.com

Frequently Asked Questions About the AZTA Investigation

Q: Which statements are being investigated as potentially misleading?A: The investigation concerns whether Azenta made materially false or misleading statements regarding its FY 2026 revenue and margin guidance, including the February 2026 reaffirmation of 3%-5% organic growth and 300 basis points of margin expansion. When the Company disclosed a $149 million goodwill impairment and cut guidance on May 5, 2026, the stock declined sharply.

Q: Who is eligible to participate in the AZTA investigation?A: Investors who purchased AZTA stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.

Q: What do AZTA investors need to do right now?A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact Levi & Korsinsky for a free, no-obligation evaluation at [email protected] or (212) 363-7500. No immediate action is required to remain eligible to participate in the investigation.

Q: What happens after I contact Levi & Korsinsky?A: An attorney will review your trading history at no cost and provide an initial assessment of your potential recovery.

Q: What if I already sold my AZTA shares -- can I still recover losses?A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought AZTA and sold at a loss may still participate in the investigation.

Q: What does it cost me to participate?A: Nothing. Securities investigations and any resulting actions are handled on a pure contingency basis. No upfront fees, no retainer, no out-of-pocket costs.

Q: What if I live outside the United States?A: U.S. securities fraud investigations generally cover purchases on U.S. exchanges regardless of the investor's country of residence.

CONTACT:\

Levi & Korsinsky, LLP\

Joseph E. Levi, Esq.\

Ed Korsinsky, Esq.\

33 Whitehall Street, 27th Floor\

New York, NY 10004\

[email protected]\

Tel: (212) 363-7500\

Fax: (212) 363-7171

SOURCE Levi & Korsinsky, LLP

On May 28, 2026, Azenta Inc AZTA shares rose 5.4%, bringing the current price to $22.49. The stock has experienced considerable volatility, with a 52-week range between $15.93 and $41.73.

GF Value™ verdict: Currently priced at $22.49, AZTA is estimated to be 64.5% undervalued relative to its GF Value™ of $63.31.GF Score™: AZTA has a score of 72/100, indicating it is ranked as Above Average in terms of potential performance.Most notable signal: Insiders have shown confidence by purchasing $0.2 million worth of stock in the last 3 months with no selling activity reported. Is AZTA Overvalued or Undervalued? The current price of Azenta Inc AZTA at $22.49 stands in stark contrast to its GF Value™ of $63.31, suggesting a potential upside of 64.5%. This significant margin of safety presents a compelling opportunity for value-oriented investors. However, it is important to note that GF Valuation has labeled AZTA as a Possible Value Trap, indicating caution should be exercised due to potential risks associated with this valuation. GF Value™ is GuruFocus' proprietary measure of intrinsic value, calculated from historical trading multiples, past business growth, and future performance estimates.

While the substantial undervaluation may attract interest, investors should consider the underlying financial metrics and overall market conditions that could impact the stock's future performance. The recent declines in the stock price over various timeframes, including a year-to-date decrease of 32.4% and a 1-year decline of 17.0%, suggest that there may be underlying issues or market sentiment affecting the stock's trajectory.

How Does AZTA's Valuation Compare to Its History? Metric Current Historical P/E (TTM) 59.3x 2.6x Azenta Inc's current P/E ratio of 59.3x is significantly above its 5-year median P/E of 2.6x. This analysis suggests that the stock is trading at a historically high valuation level, which may contradict the GF Value™ verdict indicating that the stock is undervalued. The elevated P/E ratio raises concerns regarding whether the current price reflects an accurate valuation considering historical performance ratios.

What Does AZTA's GF Score™ Tell Us? Metric Rating GF Score™ 72/100 Financial Strength 7/10 Profitability 5/10 Growth 8/10 Valuation 2/10 Momentum 5/10 The GF Score™ of 72/100 indicates that Azenta Inc has a solid potential for long-term returns, particularly driven by its Growth Rank of 8/10 and Financial Strength of 7/10. However, the Valuation Rank of 2/10 highlights that the stock may currently be overvalued in relation to its intrinsic value, suggesting that while the company has strong growth potential, its current market price does not reflect this strength adequately.

What Are Insiders Doing with AZTA Stock? Insider activity at Azenta Inc has shown a bullish sentiment, with insiders purchasing $0.2 million worth of shares in the last three months and no selling activity reported. This trend suggests that those closest to the company have confidence in its future performance and intrinsic value, which can be a positive signal for potential investors. However, it is essential to consider the broader market context and financial health of the company before drawing conclusions solely based on insider transactions.

What This Means for Investors Based on the analysis, Azenta Inc AZTA is currently undervalued according to GF Value™, with a significant margin of safety relative to its intrinsic value. However, the high P/E ratio and the possible value trap status warrant caution. Investors should weigh the potential upside against the risks associated with the current valuation and market conditions.

For the complete analysis, visit the Azenta Inc AZTA stock page. You can also explore the GF Value™ page for detailed valuation methodology, or use the GuruFocus Stock Screener to find similar opportunities.

Frequently Asked Questions What is AZTA's GF Score™?

AZTA has a GF Score™ of 72/100, indicating it is ranked as Above Average in potential performance relative to other stocks.

Is AZTA overvalued or undervalued?

According to GF Value™, AZTA is currently undervalued, with a significant margin of safety of 64.5% compared to its estimated fair value.

What is AZTA's P/E ratio?

AZTA's current P/E ratio is 59.3x, which is substantially higher than its 5-year median P/E of 2.6x, indicating the stock is trading at a much higher valuation compared to its historical performance.

This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].

, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Azenta, Inc. ("Azenta" or the "Company") (NASDAQ: AZTA).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation concerns whether Azenta and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On May 5, 2026, Azenta reported its second quarter fiscal 2026 financial results and updated its full-year outlook.  Among other items, the Company disclosed that its second quarter results "fell short" of expectations, reflecting "both execution gaps and a more cautious demand environment."  Azenta further disclosed that results were impacted by "costs related to Automated Stores rework" and that the Company recorded a $149 million non-cash goodwill impairment charge during the quarter.  In addition, Azenta reduced its fiscal 2026 outlook, stating that organic revenue was now expected to range from down approximately 2% to up 1%, compared to prior guidance of 3% to 5% growth.  The Company also reduced its adjusted EBITDA margin outlook and announced that it was extending the timeline for its long-range plan targets from 2028 to 2029.  

On this news, Azenta's stock price fell $6.23 per share, or 25.31%, to close at $18.38 per share on May 6, 2026.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.  

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

SOURCE Pomerantz LLP